Precision Medicine in Pediatric Oncology

Precision Medicine in Pediatric Oncology is organized by Physicians' Education Resource, LLC (PER).

Release Date: February 06, 2020
Expiration Date: February 06, 2021

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Overview:
This continuing medical education (CME) activity is designed to inform healthcare providers who care for pediatric oncology patients of the key principles and components of precision medicine in pediatric oncology. The in-depth program will cover the current approaches to molecular testing in the pediatric population and the genetic abnormalities that are known to be important in the setting of pediatric oncology. In addition, safety and efficacy data of ongoing trials using tropomyosin receptor kinase (TRK) inhibitors in pediatric oncology is discussed.

Benefits of Participating:
• Learn the key principles and components of precision medicine in pediatric oncology
• Outline the genetic abnormalities that are known to be important in the setting of pediatric oncology and the current approaches to molecular testing in the pediatric population
• Implement recent clinical trial findings regarding the efficacy and safety of TRK inhibitors in the treatment of pediatric patients with NTRK fusions

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Describe the key principles and components of precision medicine in pediatric hematology-oncology
• Discuss the current approaches to molecular testing in the pediatric population and the genetic abnormalities that are known to be important in the setting of pediatric oncology
• Consider safety and efficacy data of ongoing trials using tropomyosin receptor kinase (TRK) inhibitors in pediatric oncology